Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Saved in:
Bibliographic Details
Title: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Authors: Sydes MR; MRC Clinical Trials Unit at UCL, London. Electronic address: mrcctu.stampede-publications@ucl.ac.uk., Spears MR; MRC Clinical Trials Unit at UCL, London., Mason MD; Cardiff University, Cardiff., Clarke NW; Christie and Royal Salford Hospital, Manchester., Dearnaley DP; Institute of Cancer Research, Sutton., de Bono JS; Institute of Cancer Research, Sutton., Attard G; UCL Cancer Institute, University College London, London., Chowdhury S; Guy's & St Thomas NHS, Foundation Trust, London., Cross W; St James University Hospital, Leeds, UK., Gillessen S; Division of Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen; University of Bern, Bern; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland., Malik ZI; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool., Jones R; Institute of Cancer Sciences, University of Glasgow, Glasgow; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow., Parker CC; Institute of Cancer Research, Sutton; Royal Marsden Hospital, Sutton., Ritchie AWS; MRC Clinical Trials Unit at UCL, London., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow., Millman R; MRC Clinical Trials Unit at UCL, London., Matheson D; Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton., Amos C; MRC Clinical Trials Unit at UCL, London., Gilson C; MRC Clinical Trials Unit at UCL, London., Birtle A; Rosemere Cancer Centre, Royal Preston Hospital, Preston., Brock S; Dorset Cancer Centre, Poole Hospital, Poole., Capaldi L; Worcestershire Acute Hospitals NHS Trust, Worcester., Chakraborti P; Royal Derby Hospital, Derby., Choudhury A; Division of Cancer Sciences, University of Manchester, Manchester; Manchester Academic Health Science Centre, Manchester; Christie Hospital NHS Foundation Trust, Manchester., Evans L; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield., Ford D; City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham., Gale J; Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth., Gibbs S; Queen's Hospital, Romford., Gilbert DC; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton., Hughes R; Mount Vernon Group, Mount Vernon Hospital, Middlesex., McLaren D; Western General Hospital, Edinburgh., Lester JF; Velindre Cancer Centre, Cardiff., Nikapota A; Sussex Cancer Centre, Brighton., O'Sullivan J; Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast; Belfast City Hospital, Belfast., Parikh O; Lancashire Teaching Hospitals NHS Trust, Preston., Peedell C; Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough., Protheroe A; Oxford University Hospitals NHS Foundation Trust., Rudman SM; Guy's & St Thomas NHS, Foundation Trust, London., Shaffer R; Department of Oncology, Royal Surrey County Hospital, Guildford., Sheehan D; Royal Devon and Exeter Hospital, Exeter., Simms M; Hull & East Yorkshire Hospitals NHS Trust, Hull., Srihari N; Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK., Strebel R; Kantonsspital Graubünden, Chur; Swiss Group for Cancer Clinical Research (SAKK), Bern, Switzerland., Sundar S; Department of Oncology, Nottingham, University Hospitals NHS Trust, Nottingham., Tolan S; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool., Tsang D; Southend Hospital, Southend-on-Sea., Varughese M; Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust., Wagstaff J; Swansea University College of Medicine, Swansea., Parmar MKB; MRC Clinical Trials Unit at UCL, London. Electronic address: mrcctu.stampede-publications@ucl.ac.uk., James ND; Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Corporate Authors: STAMPEDE Investigators
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 May 01; Vol. 29 (5), pp. 1235-1248.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1569-8041
DOI:10.1093/annonc/mdy072